title: Stem cell transplantation and hematopoietic growth factors.
abstract: Hematopoietic growth factors are commonly used in allogeneic and autologous stem cell transplantation. The growth factors most frequently used are human recombinant erythropoietin, filgrastim, and sargramostim, and a number of trials have been done using them either singly or in various combinations for mobilization, post-transplant, and for delayed engraftment. Filgrastim and sargramostim can shorten the neutropenic period and decrease infectious complications post-transplant, thus lowering the cost of both autologous and allogeneic transplants. Erythropoietin has not been particularly effective for mobilization, and studies have not shown its efficacy in reducing red blood cell transfusions in autologous transplants. However, they have been clinically beneficial in allogeneic transplantation and in delayed erythropoiesis post-transplantation. Stem cell factor remains investigational at this time but seems promising. The new long-acting erythropoietin and filgrastim are also introduced here and briefly discussed.
authors.affiliation: Division of Hematology & Medical Oncology, Bone Marrow & Hematopoietic Stem Cell Transplantation Program, Weill Medical College of Cornell University, 520 E 70th Street, Suite ST-341, New York, NY 10021, USA. shr2002@med.cornell.edu
authors.forename: Shambavi
authors.initials: S
authors.lastname: Richard
authors.forename: Michael W
authors.initials: MW
authors.lastname: Schuster
mesh_terms: D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000379:methods; D006133:Growth Substances / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006410:Hematopoiesis / Q000187:drug effects*; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D016896:Treatment Outcome
chemical_list: D006133:Growth Substances